SOFOSBUVIR, EMTRICITABINE/TENOFOVIR (Truvada or Generic), IVM, Nirmatrelvir (Paxlovid) IN LONG COVID OR PACS. Also in Injury V and ME/CFS

[Aguirre-Chang]

DIAGNOSIS & TREATMENT AT THE SAME TIME:

THERAPEUTIC TESTS or

THERAPEUTIC CHALLENGE

For

LONG COVID

INJURY V

With:

SOFOSBUVIR

EMTRICITABINE/TENOFOVIR (Truvada or Generic)

IVM9

NIRMATRELVIR/RITONVIR (Paxlovid or Generic)

If it turns out POSITIVE

continue Treatment

https://researchgate.net/publication/371474736

 

[Aguirre-Chang]

FIRST: Answer at home, the questionnaire of the HHM Test (Hypoperfusion, Hypercoagulability and Microclots) available free of charge at: https://www.researchgate.net/publication/362634538
There is a direct correlation between the score obtained in the HHM Test, with a greater presence of Microclots (which are like Biofilms located in the blood vessels = BioClots), which in turn correlates with a higher Viral and/or Microbial Load.

 

[Aguirre-Chang]

CLINICAL CLASSIFICATION OF THE CHRONIC DISEASE OR SYNDROME ACCORDING TO THE RESULT OBTAINED IN THE HHM TEST:
10 or more points: with this score it is supported to give the Clinical Diagnosis of an HHM Syndrome associated with the presence of Microclots and Viral Persistence. In these cases it is justified to carry out the Therapeutic Test with Sofosbuvir or another Antiviral.
Between 6 to 9 points: the Risk/Benefit of performing the Therapeutic Test on the patient must be evaluated individually.
Less than 6 points: other causes should be investigated, since there are less chances of Viral Persistence.

 

[Aguirre-Chang]

SECOND: Ask the patient if he has a pathological history of allergies, asthma, chronic or recurrent rhinitis or pharyngitis, MCAS and other diseases characterized by the presence of hypersensitivity or hyperreactivity, that is, the patient's body overreacts to external agents that may be microorganisms, particles of these, toxins, metals and others. If the patient has this pathological history,
it will be classified as a patient with Hypersensitivity or Hyperreactivity.

 

[Aguirre-Chang]

THIRD: PROTOCOL TO INDICATE. In all cases, the initial Protocol will include at least the following:
1) ANTIPLATELET: It is indicated only the first 3 days: Acetylsalicylic Acid (Aspirin, other brands) 325mg after lunch. If you are a patient with Hypersensitivity, the alternatives are: Clopidogrel 75mg/día or, Ginger 1,100 mg every 12 hours or, Taxifolin 0.8 to 1mg/kg/day.
2) ANTIVIRAL: From the 4th day the following is indicated: Sofosbuvir (alone or with another antiviral) one 400 mg tablet per day, after breakfast or lunch. It is indicated for 12 continuous days, this with the objective of the Therapeutic Test to support that there is Viral Persistence. If the patient improves his symptoms by 40% or more, or 4 or more points out of 10, the Therapeutic Test is POSITIVE.
3) DIET: Low in Histamine, Nickel and Arginine. For more details, see at: https://www.researchgate.net/publication/366412536